EGFR and neoplasm: An open-label phase II single-center study of 53 patients with recurrent glioblastoma (not selected by EGFR status) found no objective tumor response with gefitinib at 500 mg daily (with protocol to escalate to 750 mg then 1000 mg as tolerated), though it was well-tolerated [62].